Bipolar Disorder Market Opportunity Assessment and Forecast Report 2024-2034 Featuring Johnson & Johnson, Otsuka, AbbVie, Bristol Myers-Squibb, OWP, Sumitomo, Pfizer [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
needs, capitalizing on late-stage pipeline products projected to influence market growth, and leveraging strategic partnerships and emerging players with strong portfolios. Dublin, Jan. 13, 2026 (GLOBE NEWSWIRE) -- The "Bipolar Disorder: Opportunity Assessment and Forecast" report has been added to ResearchAndMarkets.com's offering. This report covers the 7MM and provides an Excel-based forecast model for the Bipolar Disorder market through 2034. The bipolar disorder market is crowded with inexpensive generic products and off-label drugs.There are currently not many effective treatments targeting bipolar depression, warranting targeted drug development. In the late-stage pipeline (Phase IIb onwards), there are four products being developed to target the depressive polarity of bipolar disorder. The BD market across the 7MM was valued at $5.6 billion in the 2024 baseline year. Over the 10- year forecast period, the market is projected to grow at a compound annual growth rate (CA
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Big pharma and investors re-engage in CGTs and race to scale [Yahoo! Finance]Yahoo! Finance
- 2 Rock-Solid Dividend Stocks to Buy for Steady Passive Income [Yahoo! Finance]Yahoo! Finance
- TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide [Yahoo! Finance]Yahoo! Finance
- TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomidePR Newswire
- Update: Market Chatter: Johnson & Johnson Convinces Court to Recalculate $1 Billion Auris Award [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 10/14/25 - Beat
JNJ
Sec Filings
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- JNJ's page on the SEC website